Status:
UNKNOWN
Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma
Lead Sponsor:
Rabin Medical Center
Collaborating Sponsors:
Israeli Society for Pediatric Hematology-Oncology
International BFM Study Group
Conditions:
Childhood Leukemia and Lymphoma
Eligibility:
All Genders
Up to 30 years
Brief Summary
Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. There have been isolated case reports of patients with childhood ALL who developed LPD aft...
Detailed Description
Lymphoproliferative disorders (LPD) are a major cause of morbidity and mortality in immunodeficient patients. These disorders have been extensively described in the post-transplant setting, ie after h...
Eligibility Criteria
Inclusion
- Children and young adults treated for acute lymphoblasticleukemia/lymphoma who developed LPD after ALL/LBL diagnosis
Exclusion
- age\>30 years
Key Trial Info
Start Date :
August 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 18 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04055558
Start Date
August 25 2019
End Date
March 18 2022
Last Update
October 1 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Schneider Children's Medical Center
Petah Tikva, Israel, 4920235
2
Schneider Children's Medical Center
Petah Tikva, Israel, 4920235